Alpha Thalassemia Market Research Report - Global Forecast till 2023

Alpha Thalassemia Market Research Report - Global Forecast till 2023

ID: MRFR/HC/3712-HCRR | October, 2018 | Region: Global | 90 pages | Half-Cooked Research Reports

Alpha thalassemia market research report: by type (hb bart syndrome, hbh disease, silent carrier state, and trait.), by diagnosis (perinatal testing, prenatal testing, and pre-implantation), by treatment, by end user – Global forecast till 2023 


Market Scenario


Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin. A person is required to inherit a total of four genes to produce alpha globin protein, two of these genes are inherited from the parents. This blood disorder is caused due to abnormality or mutation in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene from parents then the person becomes a carrier of thalassemia. Since thalassemia is an inherited disorder; one of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and beta thalassemia.


Alpha thalassemia is a blood disorder that reduces the production of hemoglobin. Hb Bart syndrome is the most commonly occurring type which is characterized by hydrops fetalis, a condition in which excess fluid builds up in the body before birth.


Globally, thalassemia affects approximately 7% of the population out of which its alpha type affects 3% with many of them being transfusion-dependent patients. The global alpha thalassemia market is likely to be driven by the growing market of bone marrow transplant and blood transfusion therapy, supported by high numbers of transfusion-dependent patients. Key trends in this market include progressing drug pipeline, rising scope of gene therapy and growing awareness towards thalassemia. However, there are some factors which can hinder the growth of the market including regulatory changes, associated risks and the high cost of treatment.


The global market for alpha thalassemia is expected to grow at a CAGR of approximately 8.8% during the forecast period 2017-2023.


Intended Audience



  • Alpha thalassemia drug Suppliers

  • Alpha thalassemia drug Manufacturers

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The alpha thalassemia is segmented on the basis of type, diagnosis, treatment, and end-users.


On the basis of the type, the market is segmented into hemoglobin Bart hydrops fetalis syndrome or Hb Bart syndrome (the more severe form), HbH disease, silent carrier state, and trait.


On the basis of the diagnosis, the market is segmented into perinatal testing, prenatal testing, and pre-implantation. Further, the perinatal testing sub-categorized into complete blood count (CBC) And DNA testing. The prenatal testing further sub-segment into prenatal genetic testing and chorionic villus sampling. 


On the basis of the treatment, the market is segmented into blood transfusions, iron chelation, bone marrow, or stem cell transplant, surgery and gene therapy.


On the basis of the end-user, the market is segmented into hospitals, biotechnological laboratories, diagnostic laboratories, educational research institutes, pharmaceutical industries and others.


Regional Analysis


The global alpha thalassemia market consists of regions namely Americas, Europe, Asia Pacific, the Middle East and Africa


North America is projected to hold the largest share of the global alpha thalassemia market due to the presence of superior research and development base, strong regional economies, and greater emphasis on disease prevention and wellness by the governments. The U.S. is expected to be the first region to start selling thalassemia drugs due to developing drug pipeline and later on, market penetration of thalassemia drugs would occur in Europe. North America and Europe have a high prevalence of severe forms of alpha-thalassemia which would result in a high demand for thalassemia drugs in future.


The tropical regions are more prone to possess high numbers of patients with alpha thalassemia like Nigeria, Sudan, Chad, Columbia etc. followed by few South Asian countries. Research Institutes and Pharmaceutical companies, growing usage for alpha thalassemia testing and technological advancements, rising awareness are few factors driving market growth in the region. Few Asian countries like Myanmar and Thailand also have a high number of alpha thalassemia patients.


The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of the respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific. The thalassemia market is expected to grow in future with the mounting prevalence of thalassemia, rising Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell therapy research.


The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.


Key Players


Some of key the players in the global alpha thalassemias market are GlaxoSmithKline Plc, Celgene, Bellicum Pharmaceuticals, Lonza group, Acceleron Pharma, BlueBird Bio, Sangamo Biosciences.


The other prominent players include Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Calimmune Inc, CRISPR Therapeutics, Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics Inc and Zydus Cadila Healthcare Ltd.


Research Methodology

Alpha Thalassemia Market


Sources: Annual reports, Press release, White paper, and Company presentation





TABLE OF CONTENT





Chapter 1. Report Prologue





Chapter 2. Market Introduction





2.1 Definition





2.2 Scope of the Study





2.2.1 Research Objective





2.2.2 Assumptions





2.2.3 Limitations





Chapter 3. Research Methodology





3.1 Introduction





3.2 Primary Research





3.3 Secondary Research





3.4 Market Size Estimation





Chapter 4. Market Dynamics





4.1 Drivers





4.2 Restrains





4.3 Opportunities





4.4 Challenges





4.5 Macroeconomic Indicators





4.6 Technology Trends & Assessment





Chapter 5. Market Factor Analysis





5.1 Porter’s Five Forces Analysis





5.1.1 Bargaining Power of Suppliers





5.1.2 Bargaining Power of Buyers





5.1.3 Threat of New Entrants





5.1.4 Threat of Substitutes





5.1.5 Intensity of Rivalry





5.2 Value Chain Analysis





5.3 Investment Feasibility Analysis





5.4 Pricing Analysis





Chapter 6. Global Alpha Thalassemia Market, By Type





6.1 Introduction





6.2 Hb Bart syndrome





6.2.1 Market Estimates & Forecast, 2016 – 2023





6.3 HbH disease





6.3.1 Market Estimates & Forecast, 2016 – 2023





6.4 Silent carrier state





6.4.1 Market Estimates & Forecast, 2016 – 2023





6.5 Trait





6.5.1 Market Estimates & Forecast, 2016 – 2023





Chapter 7. Global Alpha Thalassemia Market, By Diagnosis





7.1 Introduction





7.2 Perinatal testing





7.2.1 Market Estimates & Forecast, 2017 – 2023





7.2.2 Complete blood count (CBC)





7.2.2.1 Market Estimates & Forecast, 2017 – 2023





7.2.3 DNA testing





7.2.3.1 Market Estimates & Forecast, 2017 – 2023







7.3 Prenatal testing





7.3.1 Market Estimates & Forecast, 2017 – 2023





7.3.2 Prenatal Genetic Testing





7.3.2.1 Market Estimates & Forecast, 2017 – 2023





7.3.3 Chorionic Villus sampling





7.3.3.1 Market Estimates & Forecast, 2017 – 2023





7.4 Pre-implantation





7.4.1 Market Estimates & Forecast, 2017 – 2023





Chapter 8. Global Alpha Thalassemia Market, By Treatment





8.1 Introduction





8.2 Blood transfusions





8.2.1 Market Estimates & Forecast, 2017 – 2023





8.3 Iron chelation





8.3.1 Market Estimates & Forecast, 2017 – 2023





8.4 Bone marrow, or stem cell transplant





8.4.1 Market Estimates & Forecast, 2017 – 2023





8.5 Surgery





8.5.1 Market Estimates & Forecast, 2017 – 2023





8.6 Gene therapy





8.6.1 Market Estimates & Forecast, 2017 – 2023





Chapter 9. Global Alpha Thalassemia Market, By End User





9.1 Introduction





9.2 Hospitals





9.2.1 Market Estimates & Forecast, 2017 – 2023





9.3 Biotechnological laboratories





9.3.1 Market Estimates & Forecast, 2017 – 2023





9.4 Diagnostic laboratories





9.4.1 Market Estimates & Forecast, 2017 – 2023





9.5 Educational research institutes





9.5.1 Market Estimates & Forecast, 2017 – 2023





9.6 Pharmaceutical industries





9.6.1 Market Estimates & Forecast, 2017 – 2023





9.7 Others





Chapter. 10 Global Alpha Thalassemia Market, By Region





10.1 Introduction





10.2 Americas





10.2.1 North America





10.2.1.1 U.S.





10.2.1.2 Canada





10.2.2 South America





10.3 Europe





10.3.1 Western Europe





10.3.1.1 Germany





10.3.1.2 France





10.3.1.3 Italy





10.3.1.4 Spain





10.3.1.5 U.K





10.3.1.6 Rest of Western Europe





10.3.2 Eastern Europe





10.4 Asia Pacific





10.4.1 Japan





10.4.2 China





10.4.3 India





10.4.4 Australia





10.4.5 Republic Of Korea





10.4.6 Rest of Asia Pacific





10.5 The Middle East & Africa





10.5.1 United Arab Emirates





10.5.2 Saudi Arabia





10.5.3 Rest of the Middle East & Africa





Chapter 11 Company Landscape





11.1 Introduction





11.2 Market Share Analysis





11.3 Key Development & Strategies





11.3.1 Key Developments





Chapter 12 Company Profiles





12.1 GlaxoSmithKline Plc





12.1.1 Company Overview





12.1.2 Treatment Overview





12.1.3 Financials





12.1.4 SWOT Analysis





12.2 Celgene Corporation





12.2.1 Company Overview





12.2.2 Treatment Overview





12.2.3 Financial Overview





12.2.4 Key Developments





12.2.5 SWOT Analysis





12.3 Bellicum Pharmaceuticals





12.3.1 Company Overview





12.3.2 Treatment Overview





12.3.3 Financial Overview





12.3.4 Key Development





12.3.5 SWOT Analysis





12.4 Lonza group





12.4.1 Company Overview





12.4.2 Treatment/Business Segment Overview





12.4.3 Financial Overview





12.4.4 Key Development





12.4.5 SWOT Analysis





12.5 Acceleron Pharma





12.5.1 Company Overview





12.5.2 Treatment Overview





12.5.3 Financial Overview





12.5.4 Key Developments





12.6 BlueBird Bio





12.6.1 Company Overview





12.6.2 Treatment Overview





12.6.3 Financial Overview





12.6.4 Key Developments





12.7 Sangamo Biosciences





12.7.1 Overview





12.7.2 Treatment Overview





12.7.3 Financials





12.7.4 Key Developments





12.7.5 SWOT Analysis





12.8 Johnson & Johnson





12.8.1 Company Overview





12.8.2 Treatment/Business Segment Overview





12.8.3 Financial Overview





12.8.4 Key Development





12.8.5 SWOT Analysis





12.9 Merck & Co Inc.





12.9.1 Company Overview





12.9.2 Treatment Overview





12.9.3 Financial Overview





12.9.4 Key Developments





12.10 Others





Chapter 13 MRFR Conclusion





13.1 Key Findings





13.1.1 From CEO’s View Point





13.1.2 Unmet Needs of the Market





13.2 Key Companies to Watch





13.3 Prediction of Pharmaceutical Industry





Chapter 14 Appendix





LIST OF TABLES





Table 1 Alpha Thalassemia Industry Synopsis, 2017 – 2023





Table 2 Alpha Thalassemia Market Estimates and Forecast, 2017 – 2023, (USD Million)





Table 3 Alpha Thalassemia Market by Region, 2017 – 2023, (USD Million)





Table 4 Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 5 Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 6 Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 7 Alpha Thalassemia Market by End Users, 2017 – 2023, (USD Million)





Table 8 North America Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 9 North America Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 10 North America Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 11 North America Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





Table 12 US Alpha Thalassemia Market By Type, 2017 – 2023, (USD Million)





Table 13 US Alpha Thalassemia Market By Diagnosis, 2017 – 2023, (USD Million)





Table 14 US Alpha Thalassemia Market By Treatment, 2017 – 2023, (USD Million)





Table 15 US Alpha Thalassemia Market By End User, 2017 – 2023, (USD Million)





Table 16 Canada Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 17 Canada Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 18 Canada Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 19 Canada Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





Table 20 South America Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 21 South America Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 22 South America Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 23 South America Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





Table 24 Europe Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 25 Europe Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 26 Europe Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 27 Europe Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





Table 28 Western Europe Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 29 Western Europe Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 30 Western Europe Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 31 Western Europe Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





Table 32 Eastern Europe Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 33 Eastern Europe Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 34 Eastern Europe Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 35 Eastern Europe Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





Table 36 Asia Pacific Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 37 Asia Pacific Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 38 Asia Pacific Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 39 Asia Pacific Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





Table 40 The Middle East & Africa Alpha Thalassemia Market by Type, 2017 – 2023, (USD Million)





Table 41 The Middle East & Africa Alpha Thalassemia Market by Diagnosis, 2017 – 2023, (USD Million)





Table 42 The Middle East & Africa Alpha Thalassemia Market by Treatment, 2017 – 2023, (USD Million)





Table 43 The Middle East & Africa Alpha Thalassemia Market by End User, 2017 – 2023, (USD Million)





LIST OF FIGURES





Figure 1 Research Process





Figure 2 Segmentation for Alpha Thalassemia Market





Figure 3 Segmentation Market Dynamics for Alpha Thalassemia Market





Figure 4 Global Alpha Thalassemia Market Share, By Type 2016





Figure 5 Global Alpha Thalassemia Market Share, By Diagnosis 2016





Figure 6 Global Alpha Thalassemia Market Share, By Treatment, 2016





Figure 9 Global Alpha Thalassemia Market Share, By End Users, 2016





Figure 10 Global Alpha Thalassemia Market Share, By Region, 2016





Figure 11 North America Alpha Thalassemia Market Share, By Country, 2016





Figure 12 Europe Alpha Thalassemia Market Share, By Country, 2016





Figure 13 Asia Pacific Alpha Thalassemia Market Share, By Country, 2016





Figure 14 the Middle East & Africa Alpha Thalassemia Market Share, By Country, 2016





Figure 15 Global Alpha Thalassemia Market: Company Share Analysis, 2016 (%)





Figure 16 GlaxoSmithKline Plc: Key Financials





Figure 17 GlaxoSmithKline Plc: Segmental Revenue





Figure 18 GlaxoSmithKline Plc: Geographical Revenue





Figure 19 Celgene Corporation: Key Financials





Figure 20 Celgene Corporation: Segmental Revenue





Figure 21 Celgene Corporation: Geographical Revenue





Figure 22 Bellicum Pharmaceuticals: Key Financials





Figure 23 Bellicum Pharmaceuticals: Segmental Revenue





Figure 24 Bellicum Pharmaceuticals: Geographical Revenue





Figure 25 Lonza group: Key Financials





Figure 26 Lonza group: Segmental Revenue





Figure 27 Lonza group: Geographical Revenue





Figure 28 Acceleron Pharma: Key Financials





Figure 29 Acceleron Pharma: Segmental Revenue





Figure 30 Acceleron Pharma: Geographical Revenue





Figure 32 BlueBird Bio: Key Financials





Figure 33 BlueBird Bio: Segmental Revenue





Figure 34 BlueBird Bio: Geographical Revenue





Figure 35 Sangamo Biosciences: Key Financials





Figure 36 Sangamo Biosciences: Segmental Revenue





Figure 37 Sangamo Biosciences: Geographical Revenue





Figure 38 Johnson & Johnson: Key Financials





Figure 39 Johnson & Johnson: Segmental Revenue





Figure 40 Johnson & Johnson: Geographical Revenue





Figure 41 Merck & Co Inc.: Key Financials





Figure 42 Merck & Co Inc.: Segmental Revenue





Figure 43 Merck & Co Inc.: Geographical Revenue